インスリン抵抗性(Insulin Resistance)の治療薬パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Insulin Resistance - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Insulin Resistance Overview 8
Therapeutics Development 9
Pipeline Products for Insulin Resistance – Overview 9
Pipeline Products for Insulin Resistance – Comparative Analysis 10
Insulin Resistance – Therapeutics under Development by Companies 11
Insulin Resistance – Therapeutics under Investigation by Universities/Institutes 13
Insulin Resistance – Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Insulin Resistance – Products under Development by Companies 16
Insulin Resistance – Products under Investigation by Universities/Institutes 17
Insulin Resistance – Companies Involved in Therapeutics Development 18
AUS Bio Limited 18
Genfit SA 19
GlaxoSmithKline plc 20
Hadasit Medical Research Services & Development Ltd 21
Mertiva AB 22
Mochida Pharmaceutical Co., Ltd. 23
Novartis AG 24
Prometheon Pharma, LLC 25
Sanofi 26
Thetis Pharmaceuticals LLC 27
Insulin Resistance – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
6860766 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BVS-857 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Drugs to Inhibit TRIP-Br2 for Metabolic Disorders – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Englerin A – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GFT-505 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MD-960 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PEG-Catalase – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide for Obesity and Insulin Resistance – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SAR-088 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SERX-1 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule for Hypertension and Insulin Resistance – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Target AMPD2 for Hypertension and Metabolic Disorders – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
TP-113 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Insulin Resistance – Recent Pipeline Updates 60
Insulin Resistance – Dormant Projects 66
Insulin Resistance – Product Development Milestones 67
Featured News & Press Releases 67
Oct 19, 2011: Genfit Announces Hospital-Based Clinical Study Demonstrates Action Of GFT505 On Liver 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69


【レポート販売概要】

■ タイトル:インスリン抵抗性(Insulin Resistance)の治療薬パイプライン動向(2015年上半期版)
■ 英文:Insulin Resistance - Pipeline Review, H1 2015
■ 発行日:2015年1月22日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6053IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。